Search tips
Search criteria 


Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
AAPS PharmSciTech. 2004 September; 5(3): 10–15.
Published online 2004 April 26. doi:  10.1208/pt050336
PMCID: PMC2750260

Formulation design and optimization of mouth dissolve tablets of nimesulide using vacuum drying technique


The purpose of this research was to develop mouth dissolve tablets of nimesulide. Granules containing nimesulide, camphor, crospovidone, and lactose were prepared by wet granulation technique. Camphor was sublimed from the dried granules by exposure to vacuum. The porous granules were then compressed. Alternatively, tablets were first prepared percentage friability, wetting time, and disintegration time. In the investigation, a 32 full factorial design was used to investigate the joint influence of 2 formulation variables: amount of camphor and crospovidone. The results of multiple linear regression analysis revealed that for obtaining a rapidly disintegrating dosage form, tablets should be prepared using an optimum concentration of camphor and a higher percentage of crospovidone. A contour plot is also presented to graphically represent the effect of the independent variables on the disintegration time and percentage friability. A checkpoint batch was also prepared to prove the validity of the evolved mathematical model. Sublimation of camphor from tablets resulted in superior tablets as compared with the tablets prepared from granules that were exposed to vacuum. The systematic formulation approach helped in understanding the effect of formulation processing variables.

Keywords: mouth dissolve tablet, nimesulide, camphor, factorial design, contour plot

Full Text

The Full Text of this article is available as a PDF (157K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Chang R, Guo X, Burnside B, Couch R. A review of fast dissolving tablets.Pharm Tech. (North America). June, 2000:52–58.
2. Bi Y, Sunada H, Yonezawa Y, Dayo K, Otsuka A, Iida K. Preparation and evaluation of a compressed tablet rapidly disintegrating in oral cavity. Chem Pharm Bull (Tokyo) 1996;44:2121–2127. [PubMed]
3. Corveleyn S, Remon JP. Formulation and production of rapidly disintegrating tablets by lyophilization using hydrochlorthiazide as a model drug. Int J Pharm. 1997;152:215–225. doi: 10.1016/S0378-5173(97)00092-6. [Cross Ref]
4. Remon JP, Corveleyn S. Freeze-dried rapidly disintegrating tablets. US patent 6 010 719. January 4, 2000.
5. Heinemann H, Rothe W. Preparation of porous tablets. US patent 3 885 026. May 20, 1975.
6. Knistch A, Hagen E, Munz HD. Production of porous tablets. US patent 4 134 843, January 16, 1979.
7. Roser BJ, Blair J. Rapidly soluble oral dosage forms, method of making same, and composition thereof. US patent 5 762 961. June 9, 1998.
8. Wallace JL. Prostaglandins, NSAIDs and cytoprotection. Gastroenterol Clin. North Am. 1992;21:631–641. [PubMed]
9. Singla AK, Chawla M, Singh A. Nimesulide: some pharmaceutical and pharmacological aspects and update. J Pharm Pharmacol. 2000;52:467–486. doi: 10.1211/0022357001774255. [PubMed] [Cross Ref]
10. Dapino P, Ottonello L, Dallegri F. The anti-in flammatory drug nimesulide inhibits neutrophil adherence to and migrations across monolayers of cytokine-activated endothelial cells. Respiration. 1994;61:336–341. doi: 10.1159/000196365. [PubMed] [Cross Ref]
11. Piel G, Pirotte I, Delnevvile I, Neven P, Delattre L. Study of the influence of both cyclodextrin and L-lysine on the aqueous solubility of Nimesulide: isolation and characterization of nimesulide L-lysine-cyclodextrin complexes. J Pharm Sci. 1997;86:475–480. doi: 10.1021/js960298k. [PubMed] [Cross Ref]
12. Nalluri BN, Chowdary KPR, Murthy KVR, Hayman AR, Becket G. Physicochemical characterization and dissolution properties of nimesulide-cyclodextrin binary systems. AAPS PharmSciTech. 2003;4(1):E2–E2. doi: 10.1208/pt040102. [PMC free article] [PubMed] [Cross Ref]
13. Seedher N, Bhatia S. Solubility enhancement of cox-2 inhibitors using various solvent systems. AAPS PharmSciTech. 2003;4(3):E33–E33. doi: 10.1208/pt040333. [PMC free article] [PubMed] [Cross Ref]
14. Bolton S. Pharmaceutical Statistics. 2nd ed. New York, NY: Marcel Decker Inc; 1990. pp. 234–234.
15. Franz RM, Browne JE, Lewis AR. Experiment design, modeling and optimization strategies for product and process development. In: Libermann HA, Reiger MM, Banker GS, editors. Pharmaceutical Dosage Forms: Disperse Systems. New York, NY: Marcel Dekker Inc; 1988. pp. 427–519.
16. Koizumi K, Watanabe Y, Morita K, Utoguchi N, Matsumoto M. New method of preparing high porosity rapidly saliva soluble compressed tablets using mannitol with camphor, a subliming material. Int J Pharm. 1997;152:127–131. doi: 10.1016/S0378-5173(97)04924-7. [Cross Ref]
17. Kornblum S, Stoopak S. A new tablet disintegrating agent: cross-linked polyvinylpyrollidone. J Pharm Sci. 1973;62:43–49. doi: 10.1002/jps.2600620107. [PubMed] [Cross Ref]
18. Shasaku K. Fast disintegrating solid formulations of aniretam. Jpn Kokai Tokyo Koho. Japanese patent 11 13 662. May 15, 1999.
19. Mendenhall W, Sincich T. A Second Course in Business Statistics, Regression Analysis. 3rd ed. San Francisco, CA: Dellen Publishing Co; 1989. Multiple regression; pp. 141–226.

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists